What is William Blair’s Estimate for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair raised their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued on Tuesday, January 21st. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings per share of $2.73 for the year, up from their prior estimate of $2.03. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.39 per share. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.92 EPS and FY2025 earnings at $11.70 EPS.

Several other equities research analysts also recently commented on SRPT. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective for the company. Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. HC Wainwright reissued a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, January 15th. Finally, Raymond James reaffirmed an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $116.09 on Thursday. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The company has a market cap of $11.09 billion, a PE ratio of 92.87 and a beta of 0.77. The stock has a 50-day moving average of $121.73 and a 200-day moving average of $128.78. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. CIBC Asset Management Inc boosted its stake in Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after buying an additional 103 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 138 shares during the period. Oppenheimer Asset Management Inc. grew its stake in Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.